This story has been updated to clarify that Adaptive Biotechnologies' partnership with Amgen on COVID-19 antibody development is new.
NEW YORK – Adaptive Biotechnologies is recruiting subjects for a sequencing-based study of T cell response in people who have or have been exposed to COVID-19, with designs on making the disease an early indication for the company's planned immunoSeq Dx test.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.